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Abstract
Introduction: The receptor activator of nuclear factor-kB (NF-kB) (RANK)/receptor activator of NF-kB ligand (RANKL)
axis emerges as a key regulator of breast cancer initiation, progression and metastasis. RANK receptor is a tumor
necrosis superfamily member, which upon ligand binding transduces a variety of survival, proliferation,
differentiation and migration signals. The majority of these intracellular cues merge through the NF-kB transcription
machinery.
Methods: TNFRSF11A (RANK) variants were identified and cloned in mammalian expression vectors. Their
expression was analyzed using real time PCR on RNA from normal tissue, cell lines and breast cancer specimens.
Western blot analysis and immunofluoresence stainings were used to study expression and localization of protein
isoforms in a panel of breast cancer cell lines and in transfected 293T cells. Luciferase assays were employed to
assess the contribution of each isoform alone or in combinations on NF-kB activation. Isoform effect on cell survival
after doxorubicin treatment was analyzed through MTT assay. Wound healing and transwell assays were employed
to evaluate the effect of TNFRSF11A isoforms on migration of MDA-MB-231 and 293T cells.
Results: We report the identification of three novel TNFRSF11A (RANK) variants, named TNFRSF11A_Δ9,
TNFRSF11A_Δ8,9 and TNFRSF11A_Δ7,8,9 which result from the alternative splicing of exons 7 to 9. Interestingly,
variant TNFRSF11A_Δ7,8,9 was found to be upregulated in breast cancer cells lines and its expression inversely
correlated with tumor grade and proliferation index. TNFRSF11A_Δ7,8,9 encodes a 40-45 kDa protein, we named
RANK-c, which lacks the transmembrane domain and most of the intracellular part of the wild type receptor.
Furthermore, we showed that RANK-c could act as a dominant negative regulator of RANK-dependent NF-kB
activation, affecting cell survival after apoptosis induction. In addition, RANK-c suppresses cell migration and
represses the tumorigenic properties of invasive breast carcinoma cells.
Conclusions: In this study, we provide evidence of a complex regulatory network of RANK receptor splice variants
with a role in breast cancer. We identify that the RANK-c isoform is expressed in breast cancer samples and its
expression reversely correlates with histological grade. Finally, isoform RANK-c seems to have the capacity to
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Introduction
Breast cancer is the most common malignancy, affecting
one in eight women in North America and Europe [1,2].
Recently the receptor activator of NF-kB (RANK)/
RANK ligand (RANKL) pathway was proven to be an
important regulator of the mammary stem cell (MaSC)
population [3,4] and mammary gland development
[5-7], but also, a system with a key role in breast cancer
initiation, progression [8,9] and metastasis [10,11].
The TNF receptor superfamily member, RANK (also
called TNFRSF11A, ODFR, TRANCER, CD265), is a key
regulator of T cell viability, dendritic cell function and
survival [12,13], lymph node development [14] bone
metabolism [15], and body temperature [16], through
the interaction with its ligand, RANKL (also known as
TNFSF11, ODF, TRANCE).
Despite the plethora of organs and cell types that
depend on RANK function, little is known about the regu-
latory mechanisms that govern its functions both in nor-
mal cells and cancer cells. RANK expression is reported to
be regulated at the transcriptional level through distinct
extracellular cues, such as macrophage colony-stimulating
factor (M-CSF) [17], 1alpha,25-dihydroxyvitamin D3 [18],
follicle stimulating hormone (FSH) [19], lipopolysacchar-
ide (LPS) [20] and also at the post-transcriptional level
through the action of IL-3 [21]. In addition, a recent
report provides evidence of RANK receptor shedding from
the cell surface in the mouse [22].
RANK stimulation leads to activation of the nuclear
transcription complex NF-kB in RANK-expressing
human T cells and transfected 293T cells [12], through
its long (383 amino acids) cytoplasmic domain. The NF-
kB activation is dependent on the interaction of TNF
receptor-associated factor (TRAF) adaptor proteins with
specific modules and residues of the intracellular part of
the RANK receptor, and partial or complete deletion of
these segments alter RANK signaling and thus NF-kB
activation [23]. NF-kB plays a central role in several phy-
siological and pathophysiological processes. It partici-
pates in the regulation of cell cycle progression through
its effects on cyclin D1 expression [24] and most impor-
tantly it has been implicated in the regulation of cell
death through its ability to regulate the expression of cel-
lular factors that affect the apoptotic threshold [25].
Alternative splicing (AS) is a major post-transcriptional
modification that occurs in 92 to 94% of human pre-
mRNA transcripts, through which individual mammalian
genes often produce multiple mRNA and protein iso-
forms that may have related, distinct or even opposing
functions [26]. More specifically, many cytokine recep-
tors such as IL6R, fibroblast growth factor receptor
(FGFR), IL15Ra, IL1RII, erythropoietin receptor (EPOR),
gp130, IL17R, IFNAR1 and most importantly CD40,
another TNF receptor (TNFR) family member with high
similarity to RANK, regulate part of their functions
through isoforms produced by AS [27,28].
In this study, we identified three novel variants of
TNFRSF11A, named TNFRSF11A_Δ9, TNFRSF11A_Δ8,9
and TNFRSF11A_Δ7,8,9 which result from the alter-
native splicing of exons 7 to 9. Interestingly, variant
TNFRSF11A_Δ7,8,9 was highly upregulated in breast
cancer samples and seems to encode a 40 to 50 kDa
protein, which we named RANK-c. By characterizing
the molecular and cellular properties of RANK-c in con-
junction with the other isoforms and the wild type
receptor, we showed that this novel isoform acts as a
dominant negative regulator of NF-kB through wild type
RANK, with consequences for cell survival and apopto-
sis. In addition, RANK-c seems to be a suppressor of
cell migration and represses the tumorigenic properties
of invasive breast carcinoma cells.
Materials and methods
Cell lines, antibodies and reagents
All cell lines were purchased from the American Type
Culture Collection (ATCC). MDA-MB-468, SKBR3, U87,
M059K, HeLa, Caco2, HT-29, 293T cells were grown in
DMEM with 10% fetal bovine serum (FBS). MDA-MB-
231, MCF-7 cells were cultured in Eagle’s minimum
essential medium (EMEM) with 10% fetal bovine serum
(FBS). T47D, HT-29, A549, THP-1 and Jurkat cells were
grown in Roswell Park Memorial Institute medium
(RPMI) with 10% FBS. MCF10A cells were cultured in
DMEM F12 with 5% FHS. Human skin fibroblast cell line
(1BR3) was purchased from European Collection of Cell
Cultures (ECACC) and cultured in EMEM with 15% FBS.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood of three healthy donors by centri-
fugation on Ficoll-Paque (Amersham Biosciences,
Uppsala, Sweden). The following primary antibodies were
used: anti-human RANK antibodies: (AF683, 1 μg/ml,
extracellular domain R&D systems, Abingdon, UK), (sc-
9072, 0.2 μg/ml, intracellular domain aa 317-616, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-
actin (C4, MAB1501R, 0.01 μg/ml, Chemicon, EMD
Millipore, Billerica, MA, USA) and mouse monoclonal
anti-HA (sc-57592, Santa Cruz Biotechnology Inc.).
Secondary antibodies were Alexa Fluor® 568 donkey
anti-goat (A-11057, Molecular Probes Inc., Eugene, OR,
USA) Alexa Fluor® 568 goat anti-mouse (A-11004, Mole-
cular Probes), goat anti-mouse IgG FITC (F0257, Sigma,
St. Louis, MO, USA), goat anti-rabbit IgG HRP (12-348,
Millipore, Temecula, CA, USA) and goat anti-mouse IgG
HRP (12-349, Millipore). Recombinant human sRANKL
was used in a final concentration of a 0.1 -1 μg/ml (Acris
Antibodies GmbH, Herford, Germany).
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Tissues samples and histological examination
Breast carcinoma FFPE (Formalin Fixed Paraffin
Embedded) samples were retrieved from the archives of
the Department of Pathology, General Hospital of Patras,
Agios Andreas, Greece. The selected cases comprised
invasive ductal breast carcinoma of grade 1 (three
patients), grade 2 (ten patients) and grade 3 (eight
patients). Histopathological grading (Nottingham grading
system) and immunohistochemistry evaluation of protein
markers were done as part of the routine diagnostic proce-
dure. No ethical approval and patient inform consent was
required for the present study, according to the scientific
and bioethics committee of the General Hospital of Patras,
Agios Andreas.
RNA isolation, cDNA synthesis, PCR and qRT-PCR
Total RNA from normal brain, bone marrow, thymus,
PBMCs, breast, cell lines and samples from paraffin-
embedded tissues was obtained from Biochain (Hayward,
CA, USA) or isolated using Absolutely RNA® Purification
kit (Stratagene, La Jolla, CA, USA). cDNA synthesis was
carried out using the Superscript III cDNA synthesis kit
(Invitrogen, Carlsbad, CA, USA) from 1μg of total RNA.
PCR was performed using the FastStart High Fidelity PCR
System (Roche, Mannheim, Germany). RANK variant
mRNA relative expression levels were assessed, using
gene-specific primers (Additional file 1) and the One-Step
quantitative real time (qRT)-PCR kit KAPPA SYBR FAST
(Kappabiosystems, Mowbray, South Africa) with the
Rotor-Gene 3000 (Corbett Research, Sydney, Australia).
Relative expression level of the gene of interest was calcu-
lated with the comparative 2ΔΔCt method, where ΔCt =
target Ct - control Ct, ΔΔCt =ΔCt target - ΔCt calibrator.
and all samples were normalized to the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene for PCR and to
GAPDH and human aminolevulinate delta-synthase 1
(ALAS1) (QuantiTect Primer Assay, Qiagen GmbH, Hil-
den, Germany) genes for qRT-PCR. All experiments were
independently performed in duplicate three times, each
time using 1μg of template RNA. All experimental proce-
dures that involved archived paraffin-embedded human
tissue specimens did not need any patient consent and
were conducted according to the principles laid down by
the Declaration of Helsinki.
Plasmids and transfection
PBMC cDNA was used to amplify full-length RANK var-
iants using primers P4 and P5 (Additional file 1). The
PCR products of the expected size were ligated into the
pGEM® -T Vector Systems (Promega Corp., Madison,
WI, USA) and sequenced (VBC, Austria). Inserts from
every pGEMT-RANK variant was digested with ApaI-
NotI restriction enzymes and re-ligated into pCDNA3.1/
Hygro(-) (Invitrogen).
The primers P6 and P7 (Additional file 1, Table S1),
containing restriction sites (HindIII and BamHI) were
used to amplify the RANK-c (TNFRSF11A_Δ7,8,9) open
reading frame (ORF). The PCR product was digested and
ligated into pEGFP (plasmid enhanced green fluorescent
protein) vector (Clontech, Mountain View, CA, USA) to
produce RANK-c fused to green fluorescent protein
(GFP). Human influenza hemagglutin epitope (HA)-
tagged wild type (wt) RANK and RANK-b was generated
by introducing the pCDNA3.1-RANK isoform plasmids,
one repeat of the HA at amino acid position 33 of the wt
RANK.
All PCR products were fully sequenced (VBC, Austria).
Cell transfections were performed using TurboFect™
in vitro Transfection Reagent (Fermentas GmbH,
Germany) according to the manufacturer’s instructions.
Western blotting
After 48h of transfection 293T cells were harvested and
lysed directly in SDS-PAGE loading buffer and boiled. The
supernatants from each well were collected after an addi-
tional 24 h treatment with DMEM/1% FBS and concen-
trated 4-fold in a Vivaspin 500 μl centrifugal filter unit or
left unconcentrated. Cell lysates and cell culture superna-
tants were loaded onto a 10% acrylamide gel, transferred
onto polyvinylidene difluoride (PVDF) membrane (Milli-
pore). Total Protein Western Blot (W1235086)from a
panel of human breast cancer tissues collected from three
different donors, benign lesions and normal tissue, was
purchased from Biochain.
Immunofluorescence
The 239T cells growing on polylysine-covered coverslips
were transiently transfected. After 48 h, the cells were
fixed in 4% paraformaldehyde for 10 minutes and pro-
cessed as previously described [29]. HA-tagged molecules
were visualized with the use of anti-HA (0.01 μg/ml) and
Alexa Fluor® 568 (0.005 μg/ml). Images were recorded
on a Nikon Eclipse TE 2000-U inverted microscope
using 60×/1.40 oil and 40×/0.75 lenses. ImageJ (Bethesda,
Maryland, USA) software was used to process the images.
NF-kB reporter assay
The 293T cells were seeded at a density of 1×104 cells/well
in 24-well plates, and transiently transfected with a total of
140 ng plasmid DNA (empty vector was used where
appropriate, to keep the total amount of DNA used con-
stant). The NF-kB reporter construct pNF-B-luc (Agilent
Technologies, Santa Clara, CA, USA) was used at a con-
centration of 10 ng/well. To normalize and correct for
transfection efficiency, 7ng/well of pRL-TK vector (Pro-
mega) was co-transfected. At 16h post-transfection,
RANKL was added to the cells for another 24h. Luciferase
assays were performed with the Dual-Luciferase Reporter
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assay system (Promega). Relative NF-kB/luciferase activ-
ities were normalized to Renilla luciferase expression levels
and are reported as mean values (± SD) from duplicate
transfections.
Cell proliferation assay
To determine whether RANK-c affect the proliferation
of MDA-MB-231 and 239T cell lines, the 3-(4,5-
dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide
(MTT) assay was used. Briefly, cells were plated at a
density of 2 × 10 4cells per well in 24-well tissue culture
plates and transiently transfected with the appropriate
plasmids. At 16 h post-transfection the medium was
replaced and recombinant RANKL and/or doxorubicin
were added. Cell proliferation was measured 24 h and
48 h after addition of RANKL and/or doxorubicin using
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetra-
zolium bromide) assay, as previously described [30].
Flow cytometry
The 293T transfected cells (up to 1x106) with a total of
1μg plasmid DNA (0.5 μg wt Rank + 0.5 μg mock vector,
0.5 μg Rank-c + 0.5 μg mock vector, 0.5 μg wt Rank +
0.5 μg Rank-c and 0.5μg wt Rank + 250 ng Rank-c +
250 ng mock vector) were resuspended in 100μl 1xPBS/
2%FBS/2mM EDTA and left for 10 minutes at RT (Room
Temperature) The cells were then incubated with the
mouse monoclonal anti-HA (0.004 μg/μl) for 30 minutes
at RT. After three washes with PBS/FBS/EDTA, the cells
were incubated with goat anti-mouse Ig fluorescein iso-
thiocyanate (FITC) for 10 minutes. The cells were then
washed twice with PBS and resuspended in 300 μl of ice
cold PBS. Flow cytometry was performed on an EPICS-XL
(Beckman Coulter, Inc.). Data was analyzed with FlowJo
7.6.5 software (Tree Star, Inc. Ashland, OR, USA).
Scratch motility (wound-healing) assay
Cells were plated in a six-well plate at a concentration of
5 × 105 per well and transiently transfected. At 16h post-
transfection the medium was replaced with 1% FBS and
cells were left to grow to 90% confluence. The monolayer
was scratched with a yellow pipette tip and photographed
(time 0). After 24 h, plates were photographed at the
marked spots.
Migration assay
The migration assay was performed using Transwell cham-
bers (Corning Inc., NY, USA) with 8-μm pore membranes.
MDA-MB-231 cells were transiently transfected for 16 h
and then left in full medium for 24 h. Cells were trypsi-
nized, resuspended and plated (2 × 105) into the upper
chamber containing serum-free medium, and allowed to
migrate toward 700 μl EMEM supplemented either with
1% FBS alone or recombinant RANKL (1 μg/ml). After 6 h,
the upper chamber was scraped using a cotton swab and
the cells on the lower surface of the membrane were fixed
with 4% paraformaldehyde and stained with Giemsa.
Experiments were done in triplicate and the data are pre-
sented as mean values (± SD). Three randomly chosen
fields of stained cells were counted and averaged.
Statistical analysis
Differences between groups and controls were tested by
the Student’s t-test or one-way analysis of variance
(ANOVA). To evaluate weather RANK-c mRNA levels
correlate with tumor histological grade we used the
Mann-Whitney-Wilcoxon test. Possible correlations of
protein markers (p53, Ki-67, ER, PR, Her2) and RANK-c
mRNA levels were tested using Spearman’s r correlation
coefficient. All data were analyzed with the SPSS program
(SPSS® release 15.0, Chicago, IL, USA). Any P-value less
than 0.05 was considered statistically significant.
Results
Identification of novel TNFRSF11A splice variants
differentially expressed in normal tissue and cancer
cell lines
To examine whether RANK receptor has isoforms that are
generated by alternative splicing, we isolated total RNA
from untreated PBMCs and used it for cDNA construc-
tion. The amplification of the intracellular part of the
RANK coding sequence by PCR using primers flanking
exons 6 to 9 (P1 on exon 5 and P2 on exon 10) (Addi-
tional file 1) revealed the constitutive expression of five
transcripts (five bands on the agarose gel) by non-activated
PBMCs, with approximate sizes of 1,300, 1,100, 400, 350
and 210 bp (Figure 1A). Subsequent cloning and sequen-
cing of these fragments identified the approximately 1,300
bp (1,314 bp) band as the wt TNFRSF11A transcript with
the addition of a novel exon of 148 bp named exon 9a
[HE659518: EMBL] between the already known exons 9
and 10 (Additional file 2). The approximately 1,100 bp
(1,166 bp) fragment was identified as the wt TNFRSF11A
(wt RANK), whereas the three smaller fragments were
truncated versions of the TNFRSF11A gene. The approxi-
mately 400 bp (382 bp) fragment (TNFRSF11A_Δ9) lacks
exon 9 (784 bp deletion); the approximately 350 bp (329
bp) fragment (TNFRSF11A_Δ8,9) has a deletion of exons
8 and 9 (837 bp deletion) and the smallest fragment
(TNFRSF11A_Δ7,8,9) misses exons 7, 8 and 9 (951 bp
deletion) (Figure 1A).
To determine the distribution of the TNFRSF11A tran-
scripts in adult human tissues, we performed semi-quan-
titative RT-PCR using primers P1 and P2 (Figure 1B) and
qRT-PCR (Figure 1C) employing a set of primer pairs
designed specifically for every splice variant (Additional
file 1). Most of the splice isoforms were detected in brain,
bone marrow, thymus, PBMCs and breast, whilst the
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TNFRSF11A_Δ7,8,9 variant was absent from bone mar-
row and breast. The TNFRSF11A_Δ9 transcript was
expressed at low levels in all tissue specimens tested,
whereas TNFRSF11A_Δ8,9 transcript was abundantly
expressed only in brain, thymus and breast. The wt
RANK was always expressed in all samples tested.
We sought to clone the full-length mRNAs of
TNFRSF11A (wt RANK), TNFRSF11A_Δ9, TNFRSF11A_
Δ8,9 and TNFRSF11A_Δ7,8,9. To that end we used pri-
mers P4 and P5, (Figure 2 andAdditional file 1) flanking
the initiation start codon (ATG) in exon 1 and the termi-
nation codon (TGA) in exon 10 and cloned the bands
from the anticipated molecular weights in TA vectors.
After sequencing of the cloned fragments, we identified
one clone encoding for the full-length wt TNFRSF11A and
three full-length clones encoding TNFRSF11A variants
(HE647782, HE649916, HE649917: EMBL) (Figure 2) (var-
iant TNFRSF11A_exon9a could not be identified in full-
length). The wt TNFRSF11A and the three full-length
splice variants were subcloned into mammalian expression
vectors and transiently transfected into 293T cells. Wes-
tern blot analysis of the cell pellets and cell culture super-
natants was performed, as well as immunofluorescence
(IF) stainings for isoform localization (Additional file 3).
Thus, three of the novel variants were cloned as full-
length molecules and almost all TNFRSF11A novel
variants are expressed along with wt TNFRSF11A in all tis-
sues tested. Moreover, their ratio depended on tissue type,
suggesting a tissue-dependent effect of TNFRSF11A var-
iants, and especially TNFRSF11A_Δ7,8,9, on TNFRSF11A
properties. In addition, the absence of TNFRSF11A_Δ7,8,9
variant from normal breast in conjunction with the
observed expression of this transcript in MDA-MB-468
human breast cancer cell line prompted us to further
focus on the possible roles of the TNFRSF11A variants in
breast cancer.
Figure 1 Identification and mRNA expression profile of TNFRSF11A gene variants in normal tissue. A. Agarose gel electrophoresis of the
PCR products using primers P1 and P2 on cDNA from human peripheral blood mononuclear cells (PBMCs) and the graphical representation of
the splice products identified. B. Agarose gel electrophoresis of PCR products depicting TNFRSF11A variant distribution from a panel of human
normal tissue RNAs and MDA-MB-468 as a control. C. Quantitative RT-PCR of the novel splice variants and wild type (wt) receptor activator of
NF-kB (RANK) from a panel of human normal tissue RNAs. Data normalization was carried out against the GAPDH housekeeping gene.
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TNFRSF11A_Δ7,8,9 variant is expressed in breast cancer
cell lines and breast tumors
Because of the difference in expression observed between
normal breast and breast cancer cells (MDA-MB-468) for
TNFRSF11A_Δ7,8,9, we further investigated its expression
profile. Total RNA from MCF10A, T47D, MDA-MB-231,
SKBR3, MCF-7, MDA-MB-468 cells and a panel of cell
lines (Additional file 4) was used to determine mRNA
expression by both RT-PCR and qRT-PCR.
While wt TNFRSF11A expression was detected in all
breast cancer cell lines tested, the TNFRSF11A_Δ7,8,9 var-
iant was observed only in MCF10A, T47D, MCF-7 and
MDA-MB-468 cell lines when conventional PCR and gel
electrophoresis were employed (Figure 3A). In the same
way, the use of qRT-PCR revealed the down-regulation of
the TNFRSF11A_Δ7,8,9 transcript 1.5- to 16.0-fold relative
to the non-tumorigenic epithelial cell line MCF10A, in the
breast cancer cell lines T47D, MCF-7, MDA-MB-468 and
especially in the more aggressive MDA-MB-231 and
SKBR3 (Figure 3B).
To assess the mRNA expression of the TNFRSF11A_
Δ7,8,9 variant in breast cancer tissues and correlate its
levels with protein markers, total RNA from 21 FFPE sam-
ples of invasive ductal breast carcinoma tumors was
directly used for qRT-PCR with transcript-specific primers,
as above. We observed that mRNA expression levels of the
TNFRSF11A_Δ7,8,9 inversely correlated with tumor histo-
logical grade in all tumor samples tested (P = 0.011). In
addition, further statistical analysis showed that the expres-
sion levels of TNFRSF11A_Δ7,8,9 variant decreased
Figure 2 Tumor necrosis factor receptor superfamily, member 11a (TNFRSF11A) gene organization, splice pattern, protein domain
architecture and the positions of the primers used (arrowheads). On the top: the structure of the TNFRSF11A gene with the addition of the
new exon 9a. Inside numbering represents exon length (nucleotides). Figure shows the exon organization of each alternative spliced isoform
with a representative protein structure: (i) the wt TNFRSF11A (receptor activator of NF-kB, RANK), numbering in exon boundaries indicates amino
acid residue at the splice junction, (ii) the 263-aa-residue-long RANK-a (TNFRSF11A_Δ9), encompassing SP, four extracellular TNFR repeats, TM,
and 20 aa of intracellular tail (from exon 8), (iii) the 337-aa-residue-long RANK-b (TNFRSF11A_Δ8,9) encompassing SP (signal peptide), four
extracellular tumor necrosis factor receptor (TNFR) repeats, transmembrane domain (TM) and 94 aa intracellular tail (from exon 10) and (iv) the
299-aa-residue-long RANK-c (TNFRSF11A_Δ7,8,9) encompassing SP, four extracellular TNFR repeats and 94 aa from exon 10. The arrows indicate
the translation start site and the black circle represents a stop codon. The putative protein products of exons 8, 9 and 10 are depicted as a
doted, vertically and horizontally lined box, respectively.
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significantly between groups of grade 1 and 3 (P = 0.05)
and grade 2 and 3 (P = 0.018) (Figure 3C). In contrast,
TNFRSF11A mRNA expression levels showed a tendency
to increase as the histological grade increased (Figure 3D).
Finally, among protein markers tested, proliferation index
Ki-67 showed an inverse correlation with TNFRSF11A_
Δ7,8,9 expression (P = 0.017) indicating that as breast can-
cer evolves to a more aggressive disease state the expres-
sion of the TNFRSF11A_Δ7,8,9 diminishes (Figure 3C and
Additional file 4).
TNFRSF11A_Δ7,8,9 variant encodes RANK-c, a novel RANK
protein isoform, observed in cell lines and tumor samples
The novel TNFRSF11A_Δ7,8,9 variant codes for a 299-
amino-acid (aa) RANK protein, which lacks amino acids
206 to 522 of the wt RANK. Specifically, the novel isoform
lacks the transmembrane domain (212-233aa) and a large
portion of its intracellular part (234-522aa) that includes
important functional sites (for example, 353-PSQPT-357)
of exon 9 [31]. The lack of a transmembrane segment
indicates that probably this isoform is excluded from the
Figure 3 Expression of mRNA encoding tumor necrosis factor receptor superfamily, member 11a (TNFRSF11A, wild type receptor
activator of NF-kB, wt RANK), TNFRSF11A_Δ9 (RANK-a), TNFRSF11A_Δ8,9 (RANK-b) and TNFRSF11A_Δ7,8,9 (RANK-c) in breast cancer cell
lines and breast cancer samples. A. Agarose gel electrophoresis (2%) of PCR products using primers P1 and P2 depicting TNFRSF11A and the
identified alternative splice variants in MDA-MB-231, SKBR3, MCF7, MDA-MB-468, T47D and MCF10A breast cancer cell lines. vTNFRSF11A_exon9a
was observed only in SKBR3 and after cloning and sequencing was identified as a TNFRSF11A variant encompassing exons 6, 7, 8, 9a and 10.
Splice variant TNFRSF11A_Δ7,8,9 is in bold. B. TNFRSF11A_Δ7,8,9 (RANK-c) relative mRNA expression levels in a panel of breast cancer cell lines and
the non-tumorigenic epithelial cell line MCF10A; values obtained for MCF10A were set to 100. C. Relative mRNA expression levels of variant
TNFRSF11A_Δ7,8,9 (RANK-c) in a panel of formaldehyde-fixed paraffin embedded (FFPE) invasive ductal breast carcinoma samples analyzed
against tumor histological grade and proliferation index Ki-67, respectively. D. Relative mRNA expression levels of TNFRSF11A (wt RANK) in the
same panel of invasive ductal breast carcinoma samples plotted against tumor histological grade.
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membrane and it is either in the cytoplasm or it is
secreted. The product of TNFRSF11A_Δ7,8,9 variant in
this study was named RANK-c, because it lacks three
exons and was identified as the third and smaller migrat-
ing band in our initial cloning experiments. In the same
way the putative protein products of TNFRSF11A_Δ9 and
TNFRSF11A_Δ8,9 were named RANK-a and RANK-b,
respectively.
Western blot analysis of native MCF-7 and MDA-MB-
231 cells and TNFRSF11A_Δ7,8,9 cDNA-transfected
293T cells, using the AF683 (R&D systems) anti-RANK
antibody directed against the extracellular domain of
RANK, revealed the presence of a 40-45 kDa endogenous
protein (Figure S2D in Additional file 3), which migrates
exactly the same way as exogenous RANK-c does. Both
transfected and native forms of RANK-c seem to migrate
as a double band at a higher molecular mass than that
theoretically predicted (29 kDa) possibly due to the pre-
sence of cysteine-rich regions as well as post-translational
modifications, such as glycosylation.
In addition, a commercial ready-to-use western blot
(Biochain) was employed for identification of RANK-c in
protein lysates from a panel of representative breast
tumors, benign lesions and normal tissue. Hybridization
with anti-RANK antibody (AF683, R&D systems)
revealed a band migrating approximately at 45 kDa,
resembling RANK-c (Figure S2F in Additional file 3).
Importantly, the protein expression profile of the com-
mercial blot resembled that of the mRNA, where RANK-
c is absent from normal breast but is upregulated in
low-grade and declines in high-grade tumors. Nonethe-
less, a definite identification of a native RANK-c protein
needs further experimental confirmation and probably
development of more sensitive analytical tools.
RANK-c protein isoform is a dominant negative regulator
of RANK-induced NF-kB activation
From the mRNA expression analysis in various cell lines
it appeared that TNFRSF11A variants could co-exist in
the same cell population, raising the possibility of a role
in the fine-tuning of RANK-dependent downstream sig-
naling. A major downstream ultimate target of RANK
signaling is the NF-kB transcription factor which, upon
activation, translocates to the nucleus and promotes the
transcription of numerous target genes, conferring survi-
val advantages and anti-apoptotic capacity in cells [25].
In order to characterize the role of RANK isoforms and
especially RANK-c (TNFRSF11A_Δ7,8,9) in the activation
of NF-kB, we established a dual Luciferase/NF-kB-
responsive reporter system. The 293T cells were transi-
ently transfected with the indicated RANK isoform or
were mock transfected in combination with the Luc-NF-
kB-responsive plasmid and incubated with recombinant
RANK ligand or left untreated.
As expected, wt RANK could induce the highest luci-
ferase activity, and was highly active even in the absence
of RANKL, followed by the exon 8, 9 truncated form of
RANK (RANK-b), which also showed elevated luciferase
activity in the absence of stimulus. The RANK-a
(TNFRSF11A_Δ9) isoform, which resembles a decoy
RANK receptor lacking most of the intracellular
domain, did not upregulate luciferase activity either
alone or with the addition of RANK ligand. The same
result, on luciferase activity, was observed with the
RANK-c isoform (Figure 4A). In accordance with pre-
vious results [23,32], these data indicate that the RANK
receptor is a very potent inducer of NF-kB and when
overexpressed in cells there is no requirement for
RANKL stimulation, for downstream signaling to occur.
Next we aimed to characterize the effect of the co-
expression of RANK isoforms on NF-kB activation,
because of the observed co-existence of RANK transcripts
in the same cell population. Surprisingly, when co-trans-
fecting wt RANK with the RANK-c isoform (TNFRSF11A_
Δ7,8,9), there was a significant (P < 0.001) downregulation
of luciferase activity compared to wt RANK (Figure 4B). In
contrast, none of the other isoforms were capable of inhi-
biting NF-kB activation through wt RANK, as RANK-c
did (Figure S4A in Additional file 5). Furthermore, isoform
RANK-b (TNFRSF11A_Δ8,9), which is the putative mem-
brane-bound form of RANK-c, was unable to inhibit wt
RANK-induced NF-kB activation (Figure S4B in Addi-
tional file 5). At the same time RANK-c could not inhibit
the RANK-b induced NF-kB activation, to the same extent
as for wt RANK, indicating an isoform-specific effect
(Figure S4C in Additional file 5). The same inhibitory phe-
nomenon was also observed when a GFP-RANK-c con-
struct was used in combination with wt RANK receptor
(Figure S4D in Additional file 5).
Thus, according to the luciferase data RANK-c is a
putative dominant negative regulator of RANK signaling
through NF-kB transcription factor machinery, showing
a specific effect on the wild type receptor.
Reduction of the wild type RANK on the cell surface by
expression of RANK-c isoform
To investigate the mechanism behind the effect of RANK-
c isoform on NF-kB activation through RANK, we transi-
ently transfected 293T cells with the combination of wt
HA-RANK with GFP-tagged RANK-c, or each molecule
alone. Forty-eight hours after transfection, cells were
stained with an anti-HA antibody and visualized under an
IF microscope. Interestingly, in permeabilized cells that
were double positive for HA-RANK and GFP-RANK-c
expression, both transfectants always co-localized in the
cytoplasm and HA-RANK did not show any membrane
staining (Figure 5A). However, in cells that were only HA-
RANK-positive there was a clear membrane staining
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pattern and in cells that were only GFP-RANK-c-positive
there was only cytoplasmic localization of the tagged pro-
tein. Furthermore, when the same staining procedure was
performed on non-permeabilized transfected cells, mem-
brane HA-RANK never co-localized with GFP-RANK-c-
positive cells indicating that RANK-c inhibits the translo-
cation of the wild type receptor to the cell membrane (Fig-
ure 5B and Figure S5A in Additional file 6). In addition, to
further support a possible RANK-c-induced inhibition of
wt RANK membrane translocation, we performed flow
cytometry analysis on 293T transfected cells with wt
RANK or combinations of wt RANK, RANK-b and
RANK-c. Data analysis of wt RANK and RANK-c combi-
nations, confirms the IF results and provides additional
evidence on a possible mechanism of wt RANK signaling
regulation through RANK-c (Figure 5C). Furthermore,
analysis of HA-wtRANK/RANK-b (Figure S5B in
Additional file 6) and HA-RANK-b/RANK-c (Figure S5C
in Additional file 6) indicates that the inhibition of wild
type RANK translocation to the cell membrane is RANK-
c-specific.
These results, in conjunction with the notion that wt
RANK self-associates on the cell membrane either when
overexpressed or upon RANKL stimulation [32] may
indicate one possible mechanism by which RANK-c iso-
form can regulate RANK signaling through reducing the
levels of signal-transducible, self-associated receptor on
the cell surface.
Overexpression of RANK-c inhibits the RANKL and wild
type RANK pro-survival effect after doxorubicin treatment
To characterize the cellular effects of RANK-c, either
alone or in conjunction with the wild type receptor or
RANKL treatment, we assessed cell viability after
Figure 4 Receptor activator of NF-kB (RANK)-c tumor necrosis factor receptor superfamily (TNFRSF-11A_Δ7,8,9) isoform has a
dominant negative effect on RANK/RANK ligand (RANKL)-dependent NF-kB activation. A. Expression vectors containing wild type (wt)
RANK or its isoforms were transfected in combination with a NF-kB-responsive luciferase reporter construct into 293T cells. Luciferase activity in
mock-transfected cells was set to 1. RNA was extracted from transfected cells and mRNA expression levels of the indicated isoforms were
quantified by PCR (right panel) B. Expression vectors containing RANK and RANK-c were co-transfected (at the indicated amounts) with a NF-kB-
responsive luciferase reporter construct into 293T cells. P < 0.001 between asterisk-indicated samples and wt RANK luciferase levels (untreated
and RANKL-treated, respectively). RNA was again extracted from transfected cells and mRNA expression levels of the indicated isoforms were
quantified by PCR (right panel).
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doxorubicin addition in transiently transfected MDA-
MB-231 and 293T cells.
MDA-MB-231 is reported to be a RANKL-responsive
breast cancer cell line [11] and as such we examined cell
viability after RANKL treatment. RANKL seemed to have
no effect on MDA-MB-231 cell viability and proliferation
after 48 h, when compared to untreated cells under stan-
dard culturing conditions. Then, the experiment was
repeated with the addition of 0.6 mg/ml doxorubicin and
cell viability was assessed. Interestingly, cells treated with
RANKL in the presence of doxorubicin could survive and
proliferate in contrast with untreated MDA-MB-231
cells, which in the presence of doxorubicin failed to sur-
vive and proliferate. Next, we tested how RANK-c over-
expression in MDA-MB-231 cells could affect the
RANKL pro-survival effect observed, after doxorubicin
addition. RANK-c seems to be able to significantly (P <
0.001) attenuate the pro-survival effect produced by
RANKL treatment in the MDA-MB-231 breast cancer
cell line (Figure 6A).
Furthermore, cell viability after addition of doxorubicin
(0.2mg/ml) was assessed in transiently transfected 293T
cells. The wt RANK- transfected cells were able to
endure doxorubicin cytotoxicity and this phenomenon
Figure 5 Receptor activator of NF-kB (RANK)-c reduces the levels of wild type (wt) RANK on the cell surface. A. 293T cells transiently
transfected with wt HA-RANK in combination with green fluorescent protein (GFP)-RANK-c. Cells were fixed and stained with the use of triton
0.01% for permeabilization of the cell membrane. Representative recording of a merged field (upper panel) showing the membrane localization
of a single-positive human influenza hemagglutin epitope (HA)-RANK (red) cell and the cytoplasmic retention of HA-RANK when co-expressed
with GFP-RANK-c. In the lower panel the split field of the same field in more detail. White boxes indicate the area of focus. The arrowheads
depict the clear membrane localization of wt RANK when expressed alone in a cell. B. Four representative fields of unpermeabilized (non triton)
cells fixed and stained as above. In the capture only merged fields are depicted. Split channels can be found in Additional file 6. HA molecules
were visualized with the use of anti-HA from Santa Cruz (sc-57592). C. 293T cells were transfected with HA-wt RANK alone or in combinations
with RANK-c and analysed by flow cytometry. Isotype control from mock-transfected cells (grey-filled) wt RANK is depicted by the red line and
co-transfections of wt RANK and increasing amounts of RANK-c (0.25 and 0.5μg) are depicted by blue and yellow lines, respectively. RNA was
extracted from transfected cells after flow cytometry and mRNA expression levels of the indicated isoforms were quantified by PCR (right panel).
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was reversed when wt RANK and RANK-c were co-
expressed (Figure 6B). In addition, cell death (necrosis,
late apoptosis and early apoptosis) after doxorubicin
addition in 293T cells was assessed through annexin-V/
PI staining. Total cell death was observed in approxi-
mately 22% of mock-transfected 293T cells, whilst the
introduction of wt RANK receptor cDNA significantly
(P < 0.001) reduced doxorubicin-induced toxicity 3-fold.
The effect of the wild type receptor on cell viability could
be partially reversed when the two forms of RANK
were co-expressed (P = 0.005) (Figure S6A in Additional
file 7).
These findings seem to be in line with results shown
in Figure 4, where NF-kB activation through RANK
receptor could be inhibited in the presence of RANK-c
isoform, thus down-regulating the pro-survival effect of
NF-kB activation.
Overexpression of RANK-c inhibits motility and cell
migration
The motility of mock-transfected, wt RANK and RANK-c
transfected MDA-MB-231 and 293T cells, was assessed
with the wound healing assay. Mock-transfected and wt-
transfected cells were capable of closing the wound almost
completely within 24 h, whereas RANK-c expressing cells
were less motile and showed significantly slower rates of
wound-healing (Figure 6C and Figure S6B in Additional
file 7). Furthermore, the treatment with RANKL did not
alter cell motility compared to mock and wt-transfected
cells while the combination of wt RANK/RANK-c trans-
fection produced similar results to RANK-c transfection
on MDA-MB-231 cell motility (Figure S6C in Additional
file 7).
To evaluate the role of RANK isoforms in cell migra-
tion, single-cell motility was assayed using uncoated
Figure 6 Receptor activator of NF-kB (RANK)-c regulates wild type (wt) RANK-dependent survival and inhibits cell motility and
migration. A and B. MTT proliferation/viability assays for MDA-MB-231 and 293T transfected cells, after the addition of doxorubicin (Doxo) and/
or RANK ligand (RANKL). Plasmid transfections and doxorubicin or RANKL treatments as indicated. C. RANK-c reduces the motility of MDA-MB-
231 cells, compared to both wt RANK and mock-transfected cells as assessed by the wound-healing assay. D and E. Migration of mock- and
isoform-transfected MDA-MB-231 cells towards RANKL (1 μg/ml) or 1% FBS was assessed with the use of 8-μm pore Transwell chambers. *P <
0.001 in comparison to wt RANK.
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transwells and the highly metastatic breast cancer cell
line MDA-MB-231. Plasmid constructs directing the
expression of mock, wt RANK, RANK-b (the mem-
brane-bound form of RANK-c) and RANK-c were tran-
siently transfected into MDA-MB-231 cells. Thirty-six
hours post-transfection, cells were loaded in the upper
chamber of the transwell and RANKL or 1% FBS was
used in the lower chamber as chemoattractant. Overex-
pression of wt RANK and RANK-b increased MDA-
MB-231 migration compared with mock-transfected
cells, when recombinant RANKL was used as chemoat-
tractant in the lower chamber. Furthermore, RANK-c-
transfected cells showed significantly (P < 0.001) lower
migration rates, compared to both mock-transfected and
isoform (wt RANK and RANK-b)-transfected cells (Fig-
ure 6D). Interestingly, partial inhibition of migration
was also observed for RANK-c transfected cells, even
towards 1% FBS medium, indicating a possible role for
this isoform in cytoskeleton organization and cell moti-
lity (Figure 6E). Finally, co-expression of wt RANK with
RANK-c in MDA-MB-231 cells reduced migration rates,
both towards RANKL and 1% FBS (Figure 6D and 6E),
indicating that RANK-c expression could regulate the
wild type receptor effect.
Discussion
The RANK/RANKL system is emerging as a key player in
the normal physiology of the mammary gland [5] with
significant implications in breast cancer initiation
[8,33,34], progression [9,34] and metastasis [10,11,34].
Furthermore, the RANK/RANKL pathway seems to regu-
late, in conjunction with sex hormones, proliferation and
renewal of MaSC (mammary stem cell) pool under phy-
siological conditions in normal mammary tissue but also
in breast cancer [3,4].
While this is the first report on identification of the
RANK receptor isoforms, there are already three identi-
fied RANK ligand isoforms with differential expression
patterns in bone and thymus [35]. Furthermore, RANK
ligand has been the target of extensive research during
the last decade, both at preclinical and clinical level
[36,37]. In contrast, little is known about RANK receptor
function and regulation at the molecular and cellular
level, despite its wide tissue expression profile and its
capacity to regulate divergent organs/functions (for exam-
ple, lymph node development, bone remodeling and ther-
moregulation) [12,16,38].
In this study we aimed to elucidate RANK regulation at
the post-transcriptional level through alternative splicing,
and further investigate the functional implications of the
existence of such variants on the RANK/RANKL pathway.
We were able to identify three full-length TNFRSF11A
gene variants differentially expressed between tissues and
cell lines. Interestingly, variant TNFRSF11A_Δ7,8,9 was
highly upregulated in human breast cancer samples show-
ing an inverse correlation with disease severity. The upre-
gulation of the TNFRSF11A_Δ7,8,9 variant observed in
breast cancer tissues may reflect either major changes in
the mammary cell compartment at the molecular level
[4,39] and/or changes in the tumor microenvironment,
such as immune cell infiltration (T cells, macrophages,
and so on) [39], occurring from early stages of breast
tumorigenesis. There is also the intriguing possibility that
the novel RANK variants, identified in this study, and
especially TNFRSF11A_Δ7,8,9 have roles in the regulation
of mammary stem cell and tumor-initiating cell (mam-
mary cancer stem cells) expansion and renewal capacity,
through the NF-kB machinery [40,41].
It is well established that many of the biological effects
exerted by RANK are mediated through NF-kB signaling
[42]. Because RANK variants are present in combination
with the wild type receptor in most cell lines used in this
study, we speculate a possible interaction between iso-
forms in regulating RANK signaling. Indeed, expression of
isoform combinations in 293T cells identified RANK-c
(TNFRSF11A_Δ7,8,9) as a putative dominant negative reg-
ulator of wt RANK-induced NF-kB activation. Further-
more, our data indicate that this effect is specific for
RANK-c, and isoform RANK-b (TNFRSF11A_Δ8,9), which
contains exon 7 (RANK transmembrane domain) and
represents the membrane-bound form of RANK-c, is
incapable of inhibiting NF-kB activation by RANK. In
addition, RANK-b was found to be able to activate NF-kB
in contrast to RANK-a, which seems to act as an inactive
receptor, though incapable of inhibiting RANK signaling.
The capacity of RANK-b to activate NF-kB could be
attributed to the retention of 93 amino acid residue of
cytoplasmic tail (523-616aa of the wt RANK), encompass-
ing important signaling motifs such as -IVVY- (activation
of unknown signaling pathway) [43] and -PVQEET-,
-PVQEQG- (activation of NF-kB and p38) [44]. Neverthe-
less, and despite the extensive work done on the intracel-
lular part of RANK through a panel of truncation
constructs [43-45], the exact intracellular molecules that
are able to interact with the novel RANK isoforms (for
example TRAFs) and mediate their functions, are still to
be identified.
The distinctive difference between RANK-b and
RANK-c is the exclusion of exon 7 from the latter,
affecting the localization of the protein (cytoplasmic ver-
sus membrane bound). Hence we sought to study the
localization of the wild type receptor in conjunction
with isoform RANK-c. Indeed, when both proteins were
expressed in the same cell, the presence of RANK-c iso-
form seemed to affect the capacity of the wild type
receptor to translocate to the cell surface. A similar
effect has been previously reported for CD40 variants
and wt CD40 receptor [28].
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The RANK receptor, through its interaction with
RANKL, regulates cell proliferation, survival and differen-
tiation in many cell types [5,15,46]. In addition, lately, the
RANK/RANKL system has been identified as having pro-
tumorigenic and pro-metastatic activities in various
human malignancies and specifically in breast cancer [36].
Our experimental data identified the novel isoform
RANK-c as a regulator of RANK/RANKL-dependent sur-
vival through a direct effect on wt RANK-dependent NF-
kB activation and also as an inhibitor of cell migration
through an indirect mechanism that is as yet unidentified.
The observed reduction of cell viability, when co-trans-
fecting wt RANK with RANK-c, can be attributed to the
downregulation of NF-kB. However, the inhibitory effect
on cell migration observed for RANK-c, independently of
both wt RANK transfection and RANKL stimuli, cannot
be exclusively ascribed to NF-kB regulation. A possible
explanation is provided by Armstrong and co-workers [47]
who have reported on a RANK deletion construct (RANK
Δ340-421) that lacks part of exon 9, resembling both
RANK-b and RANK-c identified in the present study,
which upon transfection was able to disrupt c-Src and c-
Cbl localization, altering cytoskeleton organization in
osteoclasts. A similar mechanism could be responsible for
the inhibition of migration observed for 293T cells and
MDA-MB-231 breast cancer cells in wound-healing and
transwell assays in this study. In addition, the lower
expression levels observed for variant TNFRSF11A_Δ7,8,9
Figure 7 Proposed model of the possible function of receptor activator of NF-kB (RANK) isoforms in fine-tuning downstream
signaling. The signaling interactions of RANK isoforms can produce divergent results on survival, differentiation, proliferation and migration
depending on expression pattern and cell type.
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(RANK-c) in high-grade, as opposed to low-grade breast
tumors in conjunction with the inhibitory effects on cell
migration, gives rise to the possibility that RANK-c could
act as a novel suppressor of metastasis. Nevertheless,
further work is needed to fully elucidate this newly charac-
terized capacity of RANK-c isoform.
An important finding of this study is the upregulation of
TNFRSF11A_Δ7,8,9 (RANK-c) in grade 1 and 2 breast
cancer tissue samples in contrast to grade 3 tissue. This
finding, independent of the cellular function of RANK-c
isoform, in conjunction with the structure of RANK-c
lacking a transmembrane domain and the identification of
this isoform in supernatants of transfected 293T cells,
indicates the possibility of a novel biomarker for breast
cancer that is related to disease severity and/or metastasis
but most importantly could be secreted.
Finally, the identification, for the first time, of multiple
TNFRSF11A transcripts provides evidence for a more
complex regulation for the RANK/RANKL system at the
receptor level [48] and a sensitive mechanism for the
receptor to fine-tune downstream signaling upon RANKL
ligation, differentially affecting cell fate (Figure 7).
Conclusions
The RANK receptor is a TNF superfamily member with
critical roles in mammary, bone and lymph node devel-
opment, but also in breast cancer initiation progression
and metastasis. In this study, we identify for the first
time, alternatively spliced variants of the RANK receptor
and provide evidence of a complex regulatory pathway
for RANK receptor signaling through its variants. The
existence of multiple variants implies a more complex
function of RANK in those cells (for example, MaSCs,
osteoclasts), tissues (for example, mammary, bone) and
tumors (for example, breast tumors) whose survival,
development and differentiation depends on expression
of the RANK receptor. Moreover, we were able to show
that isoform RANK-c is upregulated in breast cancer
samples and seems to correlate inversely with histologi-
cal grade. Furthermore, we provide experimental data
that RANK-c is a dominant negative regulator of NF-kB
activation through wt RANK and at the same time it is
a potent inhibitor of RANK-induced cell survival and
cell migration. Finally, the possibility of RANK-c being a
secreted molecule in conjunction with the fact that
RANK-c is upregulated in breast cancer, could lead to
the development of a novel biomarker for breast cancer
initiation, progression and metastasis.
Additional material
Additional file 1: A table showing primer sets and PCR cycling
conditions employed in the present study.
Additional file 2: A figure showing the identification of the novel
exon 9a of the tumor necrosis factor receptor superfamily, member
11a (TNFRSF11A) gene. A. Intron-exon boundaries of the novel exon 9a
(EMBL: HE659518). The novel exon has 148 bp length and is placed 9,772
bp downstream of exon 9 and 5346 bp upstream of exon 10 (starts at
nucleotide 58943 of NG_008098.1). B. Exon 9a spliced in between exons
9 and 10. A stop codon (TAA) is encoded in the five first nucleotides of
exon 9a when translated in silico, giving rise to a 523aa truncated form
of RANK. C. Schematic representation of RANK protein and the putative
truncated form (RANK-9a) lacking residues corresponding in exon 10. D.
Graphical representation of the putative TNFRSF11A_exon9a gene. Black
circle indicates the position of the stop codon.
Additional file 3: A figure showing Western blot analysis and
immunofluorescense staining for receptor activator of NF-kB
(RANK) receptor isoforms in transfected and non-transfected cells.
A. Western blot of transfected 293T cells with the indicated plasmid
constructs. Antibody AF683 (R&D) was used for recognition of the
extracellular part of RANK isoforms. B. Western blot of transfected 293T
cells with the indicated plasmid constructs, using antibody sc-9072
recognizing intracellular amino acids 317-616. The sc-9072 Ab is unable
to detect RANK-a (lacking intracellular aa 261-616), but identifies RANK-c
which retains aa 523-616. C. Western blot of supernatants from 293T cells
transfected with RANK-c or GFP-RANK-c as indicated. RANK-c appears as
a double band (AF683, R&D). D. Western blot of RANK-c transfected 293T
cells and cell lysates from MCF7 and MDA-MB-231 depicting (i) the
RANK-c protein migrating as a double band at approximately 40 to 45
kDa (AF683, R&D). E. Western blot from the cytoplasmic fraction of the
indicated cell lines depicting putative RANK-c protein migrating at 40 to
45 kDa and possible other RANK variants (AF683, R&D). F. Total Protein
Western Blot (W1235086, Biochain)from human breast cancer tissues,
collected from three different donors (invasive ductal carcinoma grade 2,
invasive lobular carcinoma grade 2) (AF683, R&D). G. Immunofluorescent-
stained 293T cells transfected with RANK plasmid isoforms (upper panel)
and green fluorescent protein (GFP)-RANK-c (lower panel). Antibody
AF683 was used for recognition of the extracellular part of RANK isoform,
while sc-9072 was used for recognition of the intracellular part of RANK
(aa 317-616).
Additional file 4: Figure showing mRNA expression of tumor
necrosis factor receptor superfamily, member 11a (TNFRSF11A)
variants in a panel of cell lines and TNFRSF11A_Δ7,8,9 in
formaldehyde-fixed paraffin-embedded (FFPE) samples
immunohistochemically diagnosed as ductal invasive breast
carcinoma. A. RT-PCR amplification of TNFRSF11A variants using primers
P1 and P2. TNFRSF11A variants follow a different pattern of expression in
a panel of cell lines. B. Correlation of TNFRSF11A_Δ7,8,9 mRNA levels with
histological grade and proliferation index. C. Immunoexpression of
protein markers and histological grade of 21 FFPE breast carcinoma
samples analyzed in the present study.
Additional file 5: A figure showing results of the luciferase assay for
receptor activator of NF-kB (RANK) isoform-induced NF-kB
activation. A. Luciferase assay depicting the downregulation of NF-kB
activation produced by the combined transfection of wild type (wt)
RANK and RANK-c, but not with any other combination. *P < 0.001
between wt RANK- and RANK-c-treated (RANKL) and untreated. B. Co-
transfection of 293T cells with wt RANK and RANK-b (as indicated), does
not affect NF-kB activation. C. Co-transfection of 293T cells with RANK-b
and increasing amounts of RANK-c. RANK-c seems able to downregulate
NF-kB activation, though not to the same extent as for wt RANK. RT-PCR
on total RNA isolated from transfected cells, serving as a transfection
control (right panel). D. Co-transfection of 293T cells with wt RANK and
increasing amounts of green fluorescent protein (GFP)-RANK-c. The GFP
tagged RANK-c seems to have the same effect on wt receptor NF-kB
activation, as does RANK-c. RT-PCR on total RNA isolated from
transfected cells, serving as a transfection control (right panel).
Additional file 6: A figure showing flow cytometry analysis of 293T
cells, transfected with combinations of various receptor activator of
NF-kB (RANK) isoforms. A. Non-permeabilized transfected 293T cells
with both human influenza hemagglutin epitope (HA)-RANK and green
fluorescent protein (GFP)-RANK-c plasmids. HA molecules were visualized
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with the use of anti-HA from Santa Cruz (sc-57592). B. Flow cytometry
analysis of 293T cells co-transfected with HA-wild type (wt) RANK and
RANK-b, indicating that RANK-b is unable to inhibit HA-wt RANK
translocation to the cell membrane. C. 293T cells were transfected with
HA-RANK-b alone or in combination with RANK-c. Flow cytometry
analysis demonstrates that RANK-c is incapable to inhibit HA-RANK-b
translocation to the cell surface.
Additional file 7: A figure showing the flow cytometry viability
assay and wound-healing assay for 293T and MDA-MB-231 cells
after transfection with the indicated receptor activator of NF-kB
(RANK) isoform. A. 293T cells were plated (1 × 105) in twelve-well plates
and transiently transfected with the respective constructs. At 24 h post-
transfection doxorubicin HCL (Ebewe Pharma, Austria) (0.2 mg/ml) was
added for another 24 h. At the end of the 24 h-doxorubicin-incubation,
cells were washed twice with PBS and trypsinized. Cells were stained for
annexin V-FITC and propidium iodide (PI) (rh Annexin V/FITC kit, Bender
MedSystems) and were immediately analyzed by flow cytometry (EPICS-
XL, Coulter) according to manufacturer’s instructions. Double-positive
cells were considered as late apoptotic, PI single-positive cells or Annexin
V single-positive cells were considered necrotic and early apoptotic,
respectively. All treatments were done in duplicate and experiments
were repeated at least twice. B. RANK-c reduces the motility of 293T
cells, compared to both wild type (wt) RANK and mock-transfected cells
as assessed by the wound-healing assay. C. Wound healing assay of
MDA-MB-231 cells either transfected with wt RANK/RANK-c plasmids or
treated with RANKL.
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